Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (The Lancet (2010) 376(9742) (705–716) (S0140673610609348) (10.1016/S0140-6736(10)60934-8));Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial

The Lancet

Volumn 376, Issue 9742, 2010, Pages 705-716

  Kwo, Paul Y ^a   Lawitz, Eric J ^b   McCone, Jonathan ^c   Schiff, Eugene R ^d   Vierling, John M ^e   Pound, David ^f   Davis, Mitchell N ^g   Galati, Joseph S ^h   Gordon, Stuart C ⁱ   Ravendhran, Natarajan ^j   Rossaro, Lorenzo ^k   Anderson, Frank H ^l   Jacobson, Ira M ^m   Rubin, Raymond ⁿ   Koury, Kenneth ^o   Pedicone, Lisa D ^o   Brass, Clifford A ^o   Chaudhri, Eirum ^o   Albrecht, Janice K ^o  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Alamo Medical Research   (United States)

^c Mount Vernon Endoscopy Center   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Indianapolis Gastroenterology Research Foundation   (United States)

^g Digestive CARE South Florida Center of Gastroenterology   (United States)

^h Liver Specialists of Texas   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j ST AGNES HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Liver and Intestinal Research Centre   (Canada)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ Liver Center of Atlanta   (United States)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSGEUSIA; EVENING DOSAGE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; HEPATITIS C, CHRONIC; MIDDLE AGED; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77956268467     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61882-X     Document Type: Erratum

References (28)

1. EC Verna, RS Brown Jr Hepatitis C virus and liver transplantation Clin Liver Dis 10 2006 919 940
2. GM Lauer, BD Walker Hepatitis C virus infection N Engl J Med 345 2001 41 52
3. JG McHutchison, EJ Lawitz, ML Shiffman Peginterferon ab or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
4. MP Manns, JG McHutchison, SC Gordon for the International Hepatitis Interventional Therapy Group Peginterferon alfa-2b plus ribavirin compared with interferon ab plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
5. MW Fried, ML Shiffman, KR Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
6. AJ Muir, JD Bornstein, PG Killenberg Atlantic Coast Hepatitis Treatment Group Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2004 2265 2271
7. HS Conjeevaram, MW Fried, LJ Jeffers Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 2006 470 477
8. T Poynard, JG McHutchison, MP Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
9. GL Davis, JB Wong, JG McHutchison, MP Manns, J Harvey, J Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
10. P Ferenci, MW Fried, ML Shiffman Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433
11. DM Jensen, TR Morgan, P Marcellin Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960
12. S Zeuzem, M Buti, P Ferenci Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 2006 97 103
13. BH McGovern, Dayyeh BK Abu, RT Chung Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection Hepatology 48 2008 1700 1712
14. BA Malcolm, R Liu, F Lahser SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020
15. C Sarrazin, R Rouzier, F Wagner SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
16. E Schiff, E Poordad, I Jacobson Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness J Hepatol 48 2008 S46S
17. JG McHutchison, GT Everson, SC Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
18. C Hézode, N Forestier, G Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
19. P Kwo, E Lawitz, K McCone Response-guided therapy (RGT) for boceprevir (BOC) combination treatment? Results from HCV SPRINT-1 Hepatology 50 suppl 4 2009 1035A 1036A (abstr).
20. P Kwo, E Lawitz, J McCone High sustained virologic response (SVR) in genotype 1 (G1) null responders to peg-interferon alfa-2b (P) plus ribavirin (R) when treated with boceprevir (BOC) combination therapy Hepatology 50 suppl 4 2009 331A 332A (abstr).
21. K Berman, PY Kwo Boceprevir, an NS3 protease inhibitor of HCV Clin Liver Dis 13 2009 429 439
22. L Wood, M Egger, LL Gluud Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study BMJ 336 2008 601 605
23. S Susser, C Welsch, Y Wang Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
24. C Sarrazin, TL Kieffer, D Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
25. X Tong, R Chase, A Skelton, T Chen, J Wright-Minogue, BA Malcolm Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 2006 28 38
26. X Tong, S Bogen, R Chase Characterization of resistance mutations against HCV ketoamide protease inhibitors Antiviral Res 77 2008 177 185
27. S Curry, P Qiu, X Tong Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay J Virol Methods 153 2008 156 162
28. M Sulkowski, M Shiffman, N Afdhal Hemoglobin decline is associated with SVR among HCV genotype 1-infected persons treated with peginterferon (PEG)/ribavirin (RBV): analysis from the ideal study J Hepatol 50 2009 s51